Faculty profile

Joel Lexchin

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Joel Lexchin

Researcher

Social Sciences and Humanities

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
53 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (5 CIHR, 1 SSHRC), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

170

Publications

571

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

podcast knowledge mobilization policy pharmaceutical drugs

Latest papers

Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study.
Journal of general internal medicine · 2026 · first author
Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.
BMJ open · 2026
Risk management plans and drug safety in Canada: A cross-sectional study.
The International journal of risk & safety in medicine · 2026 · first author

All 170 publications

Latest funding

Safety Advisories Framework for Effective Risk communication - Phase 2 (SAFER-2)
CIHR · 2024 · Co-investigator
$753,524
Strengthening Canada's Drug Supply Chain: Establishing the Canadian Drug Shortage Observatory
CIHR · 2024 · Co-investigator
$100,000
Beyond public payment, private delivery: Understanding how private financing and for-profit delivery operate within Canadian health care
CIHR · 2022 · Principal investigator
$149,650

All 10 grants and awards

From the 150 most recent of 170 publications.

Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study.

Lexchin J

Journal of general internal medicine2026First author

DOI: 10.1007/s11606-026-10608-y PMID: 42373964

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

Grundy Q, Hart D, Lexchin J, Persaud N, Tadrous M, Gagnon MA

BMJ open2026

DOI: 10.1136/bmjopen-2026-117321 PMID: 42259567

Risk management plans and drug safety in Canada: A cross-sectional study.

Lexchin J

The International journal of risk & safety in medicine2026First author

DOI: 10.1177/09246479251414280 PMID: 41456151

Joint working between the NHS and pharma-do the claims add up?

Wilcock M, Lexchin J

Drug and therapeutics bulletin2026Senior author

DOI: 10.1136/dtb.2025.000031 PMID: 41927353

Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study.

Rickard E, Lexchin J

PloS one2026Senior author

DOI: 10.1371/journal.pone.0348311 PMID: 42133663

Addressing the challenge of post-approval regulation of pharmaceuticals: The case for independent third-party evaluations.

Bavli I, Sadaka Y, Yanover C, Lexchin J

Health policy (Amsterdam, Netherlands)2026Senior author

DOI: 10.1016/j.healthpol.2026.105585 PMID: 41724137

Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study.

Lexchin J

Health policy (Amsterdam, Netherlands)2026First author

DOI: 10.1016/j.healthpol.2026.105631 PMID: 41950560

Doctors' Conflict-of-Interest; What it Looks Like and What to do About it.

Lexchin J

International journal of social determinants of health and health services2026First author

DOI: 10.1177/27551938261431289 PMID: 41854366

Drugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990-2024: A Cross-Sectional Study.

Lexchin J

Drug safety2026First author

DOI: 10.1007/s40264-025-01612-y PMID: 40931269

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta-analysis.

Hooimeyer A, McEwin EJ, Wang Z, Lexchin J, Mintzes B

British journal of clinical pharmacology2026

DOI: 10.1002/bcp.70486 PMID: 41717670

Safety Advisories Framework for Effective Risk communication - Phase 2 (SAFER-2)

Co-investigatorCIHR2024Project Grant

Principal investigators: Dormuth, Colin R; Mintzes, Barbara J; Otte, Jessica

Keywords: Co-Design; Drug Utilization Research; Focus Groups; Knowledge Translation Exchange; Medication Safety; Quality Improvement; Risk Communication

$753,524

Strengthening Canada's Drug Supply Chain: Establishing the Canadian Drug Shortage Observatory

Co-investigatorCIHR2024Project Grant - Priority Announcement: Global Health Research - CRPPHE

Principal investigators: Tadrous, Mina; Ahmed, Saad; Beall, Reed; Fahim, Christine; Gomes, Tara

Keywords: Drug Safety; Drug Shortages; Health Outcomes; Health Policy; Pharmaceutical; Supply Chain

$100,000

Beyond public payment, private delivery: Understanding how private financing and for-profit delivery operate within Canadian health care

Principal investigatorCIHR2022Cat Gr:Policy Res. for Health Sys. Transf.- Canadian Healthcare Workforce

Principal investigators: Hedden, Lindsay K; Lexchin, Joel

Keywords: For-Profit; Health Care Delivery; Health Care Financing; Health Policy; Privatization

$149,650

A Documentary Mini-Series Examining Pharmaceutical Policy

Principal investigatorSSHRC2018Connection Grants

Principal investigators: Lexchin, Joel

Keywords: podcast; knowledge mobilization; policy; pharmaceutical; drugs

$48,000

Beyond Transparency in Pharmaceutical Research and Regulation

Principal investigatorCIHR2017Project Grant

Principal investigators: Herder, Matthew; Graham, Janice E; Lemmens, Trudo; Lexchin, Joel

Keywords: Drug Safety; Law; Pharmaceutical Policy; Regulation

$489,600

What works best to protect public health? An international comparison of post-market regulatory risk communication on prescription drugs

Co-investigatorCIHR2016Project Grant

Principal investigators: Dormuth, Colin R; Mintzes, Barbara J; Sketris, Ingrid S

Keywords: Drug Utilization Research; International Comparison; Key Informant Interviews; Medication Safety; Pharmacoepidemiology; Regulatory Policy; Risk Communication; Systematic Review

$1,158,976

When Treatments Harm: Building Better Systems and Enhancing Research Capacity to Reduce Adverse Drug Events

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Hohl, Corinne M

Keywords: Adverse Drug Events; Clinical Decision Rule; Drug Safety And Effectiveness; Emergency Medicine; Internal Medicine; Patient Safety; Surveillance

$1,160,050

Adverse Drug Event Reporting in PharmaNet to Improve Patient Safety and Inform Policy

Principal investigatorCIHR2012Partnerships for Health System Improvement (PHSI)

Principal investigators: Hohl, Corinne M; Taylor, Amy; Balka, Ellen; Coleman, Jeff; Lexchin, Joel; Sobolev, Boris G

Keywords: Adverse Drug Event Reporting; Communication Across Healthcare Sectors; Drug Safety; Electronic Medical Records; Medication Information Systems; Pharmacosurveillance; Prevention

$596,000

Planning the Evaluation of Medication Review in Emergency Department Patients

Principal investigatorCIHR2012Planning Grants - Priority Announcement: Health Services and Policy Research

Principal investigators: Hohl, Corinne M; Lexchin, Joel; Sobolev, Boris G

Keywords: Adverse Drug Events; Community-Based Primary Healthcare; Drug Safety And Effectiveness; Emergency Medicine; Medication Review; Planning; Team Building

$24,997

Pharmaceutical Sales Representatives and Patient Safety: exploration of physician experiences in three countries and implications for regulatory policy

Principal investigatorCIHR2011Operating Grant

Principal investigators: Mintzes, Barbara J; Lexchin, Joel

Keywords: Comparison Of National Regulatory Policies; Cross-Sectional Survey; Drug Promotion; Family Practice; Focus Groups; Patient Safety; Pharmaceutical Policy; Policy Analysis

$247,925

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Joel Lexchin

Research

Latest papers

Latest funding

Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study.

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

Risk management plans and drug safety in Canada: A cross-sectional study.

Joint working between the NHS and pharma-do the claims add up?

Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study.

Addressing the challenge of post-approval regulation of pharmaceuticals: The case for independent third-party evaluations.

Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study.

Doctors' Conflict-of-Interest; What it Looks Like and What to do About it.

Drugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990-2024: A Cross-Sectional Study.

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta-analysis.

A Documentary Mini-Series Examining Pharmaceutical Policy

Frequent collaborators

Barbara Mintzes

An-Wen Chan

Mary Wiktorowicz

Anne Marie Holbrook

Paul Grootendorst

Derelie A Mangin

Matthew Herder

Navindra Persaud

Mina Tadrous

Boris Sobolev

Pat Armstrong

Devon Greyson

Kimberlyn McGrail

Lisa Forman

Trudo Lemmens

Andrea Benedetti

Gordon Guyatt

Jason Sutherland

Nicholas King

Meredith Vanstone